Download Files:
Plogosertib
$280 – $6,800
Products Details
Product Description
– Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers[1][2].
Web ID
– HY-147298
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C34H48N8O3
References
– [1]Sylvie Moureau, et al. Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Cancer Res (2017) 77 (13_Supplement): 4178.|[2]Moureau S, et al. Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia[J]. European Journal of Cancer, 2016, 1(69): S117. |[3]Susan Davis, et al. Treatment of proliferative diseases with pyrimidodiazepinones. Patent US20150320762A1.
CAS Number
– 1137212-79-3
Molecular Weight
– 616.80
Compound Purity
– 99.95
SMILES
– O=C1C2(CC2)CN(C3CCCC3)C4=NC(NC5=C(C=C(C=C5)C(N[C@@H]6CC[C@@H](N7CCN(CC7)C)CC6)=O)OC)=NC=C4N1C
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Polo-like Kinase (PLK)
Isoform
– PLK1;PLK2;PLK3
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
